A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/L in HIV-infected patients with CD4 counts remaining between 101-350 cells/mL after at least 2 years of HAART and plasma HIV RNA < 50 copies/mL for 18 months.

Trial Profile

A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/L in HIV-infected patients with CD4 counts remaining between 101-350 cells/mL after at least 2 years of HAART and plasma HIV RNA < 50 copies/mL for 18 months.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2016

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms INSPIRE-3
  • Most Recent Events

    • 07 Feb 2016 Pooled analysis of 2 studies including this INSPIRE 3 trial and other INSPIRE 2 study [see CTP 700052537] were published in the Clinical Infectious Diseases.
    • 24 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Oct 2012 Planned End Date changed from 1 Jul 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top